Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Author Correction: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study.
Scagnoli S, Pisegna S, Toss A, Caputo R, De Laurentiis M, Palleschi M, de Giorgi U, Cortesi E, Fabbri A, Fabi A, Paris I, Orlandi A, Curigliano G, Criscitiello C, Garrone O, Tomasello G, D'Auria G, Vici P, Ricevuto E, Domati F, Piombino C, Parola S, Scafetta R, Cirillo A, Taurelli Salimbeni B, Di Lisa FS, Strigari L, Preissner R, Simmaco M, Santini D, Marchetti P, Botticelli A. Scagnoli S, et al. Among authors: pisegna s. NPJ Breast Cancer. 2024 Aug 2;10(1):68. doi: 10.1038/s41523-024-00682-y. NPJ Breast Cancer. 2024. PMID: 39095493 Free PMC article. No abstract available.
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study.
Scagnoli S, Pisegna S, Toss A, Caputo R, De Laurentiis M, Palleschi M, de Giorgi U, Cortesi E, Fabbri A, Fabi A, Paris I, Orlandi A, Curigliano G, Criscitiello C, Garrone O, Tomasello G, D'Auria G, Vici P, Ricevuto E, Domati F, Piombino C, Parola S, Scafetta R, Cirillo A, Taurelli Salimbeni B, Di Lisa FS, Strigari L, Preissner R, Simmaco M, Santini D, Marchetti P, Botticelli A. Scagnoli S, et al. Among authors: pisegna s. NPJ Breast Cancer. 2024 Jul 17;10(1):58. doi: 10.1038/s41523-024-00657-z. NPJ Breast Cancer. 2024. PMID: 39019916 Free PMC article.
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study.
Botticelli A, Caputo R, Scagnoli S, Pisegna S, De Laurentiis M, Curigliano G, Lambertini M, Pantano F, Palazzo A, Paris I, Vernieri C, Tedesco B, Giampaglia M, Palleschi M, Ballatore Z, Alesini D, D'Auria G, Fabbri A, Rossi L, Verrazzo A, Scafetta R, Marinelli D, Sposetti C, Barberi V, Strigari L, Marchetti P, Santini D, Fabi A. Botticelli A, et al. Among authors: pisegna s. Oncologist. 2024 Apr 4;29(4):303-310. doi: 10.1093/oncolo/oyad308. Oncologist. 2024. PMID: 37995313 Free PMC article.
The Impact of Drug-Drug Interactions on the Toxicity Profile of Combined Treatment with BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic Melanoma.
Mezi S, Botticelli A, Scagnoli S, Pomati G, Fiscon G, De Galitiis F, Di Pietro FR, Verkhovskaia S, Amirhassankhani S, Pisegna S, Gentile G, Simmaco M, Gohlke B, Preissner R, Marchetti P. Mezi S, et al. Among authors: pisegna s. Cancers (Basel). 2023 Sep 15;15(18):4587. doi: 10.3390/cancers15184587. Cancers (Basel). 2023. PMID: 37760556 Free PMC article.
The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy.
Botticelli A, Pomati G, Cirillo A, Scagnoli S, Pisegna S, Chiavassa A, Rossi E, Schinzari G, Tortora G, Di Pietro FR, Cerbelli B, Di Filippo A, Amirhassankhani S, Scala A, Zizzari IG, Cortesi E, Tomao S, Nuti M, Mezi S, Marchetti P. Botticelli A, et al. Among authors: pisegna s. Front Immunol. 2022 Nov 3;13:974087. doi: 10.3389/fimmu.2022.974087. eCollection 2022. Front Immunol. 2022. PMID: 36405727 Free PMC article.
Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study.
Fabbri A, Nelli F, Botticelli A, Giannarelli D, Marrucci E, Fiore C, Virtuoso A, Scagnoli S, Pisegna S, Alesini D, Sini V, Orlandi A, Fabi A, Piacentini F, Moscetti L, D'Auria G, Gamucci T, Mazzotta M, Pizzuti L, Vici P, Cretella E, Scavina P, La Cesa A, Persano M, Atzori F, Ruggeri EM. Fabbri A, et al. Among authors: pisegna s. Front Oncol. 2023 Jun 27;13:1177681. doi: 10.3389/fonc.2023.1177681. eCollection 2023. Front Oncol. 2023. PMID: 37441419 Free PMC article.
Immune responses and clinical outcomes following the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in advanced breast cancer patients receiving targeted therapies: a prospective study.
Nelli F, Fabbri A, Botticelli A, Giannarelli D, Marrucci E, Fiore C, Virtuoso A, Berrios JRG, Scagnoli S, Pisegna S, Cirillo A, Panichi V, Massari A, Silvestri MA, Ruggeri EM. Nelli F, et al. Among authors: pisegna s. Front Oncol. 2023 Nov 7;13:1280416. doi: 10.3389/fonc.2023.1280416. eCollection 2023. Front Oncol. 2023. PMID: 38023235 Free PMC article.
Clinical implications of the Drug-Drug Interaction in Cancer Patients treated with innovative oncological treatments.
Santamaria F, Roberto M, Buccilli D, Di Civita MA, Giancontieri P, Maltese G, Nicolella F, Torchia A, Scagnoli S, Pisegna S, Barchiesi G, Speranza I, Botticelli A, Santini D. Santamaria F, et al. Among authors: pisegna s. Crit Rev Oncol Hematol. 2024 Aug;200:104405. doi: 10.1016/j.critrevonc.2024.104405. Epub 2024 Jun 3. Crit Rev Oncol Hematol. 2024. PMID: 38838928 Review.
Tissue Immune Profile: A Tool to Predict Response to Neoadjuvant Therapy in Triple Negative Breast Cancer.
Cerbelli B, Scagnoli S, Mezi S, De Luca A, Pisegna S, Amabile MI, Roberto M, Fortunato L, Costarelli L, Pernazza A, Strigari L, Della Rocca C, Marchetti P, d'Amati G, Botticelli A. Cerbelli B, et al. Among authors: pisegna s. Cancers (Basel). 2020 Sep 16;12(9):2648. doi: 10.3390/cancers12092648. Cancers (Basel). 2020. PMID: 32947953 Free PMC article.
23 results